NewCardio Company Description
NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development.
The company’s technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes.
Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data.
The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space.
NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Jess Jones |
Contact Details
Address: PO Box 658 Branchburg, Delaware 08853 United States | |
| Phone | 877-332-4324 |
Stock Details
| Ticker Symbol | NWCI |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US28257U1043 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jess Emery Jones M.D. | Chief Executive Officer and Director |
| Greg Sadowski | Chief Operating Officer |